tariffs – Talk Bio

EMD Serono Joins TrumpRx in Affordability Push; Roche Launches DTC Program

1 week ago talkbio0Tagged Affordability, CNPV, direct-to-consumer sales, Ditiocarb, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Pergoveris, Programs - Publication Format, Roche (company), serono, tariffs, TrumpRx, White House Executive Order

EMD Serono; TrumpRx; IVF therapies; affordability; fertility drugs; Direct-to-Consumer sales; Roche; DTC program; White House Executive Order; Section 232 tariffs; CNPV program; Pergoveris

AstraZeneca Reaches Drug Pricing Deal with White House, Becomes Second Pharma to Do So

2 weeks ago talkbio0Tagged AstraZeneca, drug discounts, drug price, Medicaid, most-favored-nation pricing, Pfizer, tariffs, TrumpRx, White House

AstraZeneca; White House; drug pricing; Medicaid; TrumpRx; most-favored-nation pricing; tariffs; Pfizer; drug discounts

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

4 weeks ago talkbio0Tagged Commitment Deadline, direct-to-consumer sales, drug price, executive order, international reference price, Medicaid, MFN, Most-Favored-Nation, Parity, pharmaceutical manufacturers, Prices, Pricing, tariffs, Transplant Registry Unified Management Program

Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

1 month ago talkbio0Tagged Evaluation, Manufacturing, Medical Devices, medtech industry, National Security, pharmaceutical imports, Sectioning technique, semiconductor tariffs, supply chain, tariffs, Transplant Registry Unified Management Program

Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices

Trump’s Most Favored Nation Policy and EU Generics: Recent Developments

2 months ago talkbio0Tagged drug price, EU, generics, Nation, Pharma, Policy, tariffs, Transplant Registry Unified Management Program

Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma

Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats

3 months ago talkbio0Tagged Albert Bourla, Direct-to-Consumer, Drug Industry, drug price, Jr., Mehmet, Nation, negotiation, ounce, Pfizer, PhRMA, Policy, Pricing, Robert F. Kennedy, tariffs, Trump administration

Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA

AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

3 months ago talkbio0Tagged AstraZeneca, Chronic disease, Investments, Manufacturing, R&D, Surgical construction, tariffs, United States, Virginia plant

AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals

Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty

3 months ago talkbio0Tagged Donald Trump, Drug Industry, drug price, Health Care Systems, Manufacturing, onshoring, supply chains, tariffs

pharmaceutical industry; tariffs; Donald Trump; supply chains; onshoring; drug prices; manufacturing; healthcare system

Sanofi Announces $20 Billion US Investment Over Five Years

5 months ago talkbio0Tagged Big Pharma, development aspects, domestic partnerships, Drug Industry, Investments, Manufacturing, research, sanofi, Surgical construction, tariffs, U.S.

Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships

Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table

6 months ago talkbio0Tagged Bourla, M&A, Pfizer, Policy, tariffs, TNFRSF19 gene, United States

Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs